• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • scFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing Service
  • CAR Cell In Vitro Assay Service
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trials
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Analysis
  • TCR Clinical Applications
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-stop CAR-NKT Therapy Development
  • One-stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering Service
  • NK Cell Expansion Service
• One-stop Cytokine Release Syndrome (CRS) Management Solutions
• One-Stop CAR-B Therapy Development
• TCR-Like Antibody Development Service
  • MHC/Peptide Complex Production for TCR-Like Antibody Discovery
  • TCR-Like Antibody Discovery Strategies
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction and Evaluation Service
• γδ T Cells Engineering Services
• One-Stop Canine CAR-T Therapy Development Services
  • Canine CAR-T Engineering Service
  • Canine CAR-T Development Service for Hematologic Malignancies
  • Canine CAR-T Development Service for Solid Tumor
  • Canine CAR-T Cell Characterization Service
• CellRapeutics™ In Vivo Cell Engineering Development Services
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• scFv-TCR T Cell Therapy Development Service
• One-Stop Silence™ CAR-T Cell Therapy Development Services
• One-Stop mRNA CAR-T Therapy Development
• Vaccine Boosting CAR-T Cell Therapy Solutions Against Solid Tumors
  • Peptide-DC Vaccine Boosting pMHC-directed CAR-T Cell Solutions
  • Amphiphile-ligand Vaccine Boosting CAR-T Cell Solutions
  • RNA Vaccine Boosting CAR-T Cell Solutions
  • Virus-based Vaccine Boosting CAR-T Cell Solutions
• CellRapeutics™ STAb-T Cell Therapy Development
• CellRapeutics™ CART Therapy Development Services in the Non-Cancer Field
  • CellRapeutics™ CART Development Service for Autoimmune Diseases
  • CellRapeutics™ CART Development Service Powering Anti-Aging Field
  • CellRapeutics™ CART Development Service for Fibrotic Diseases
  • CellRapeutics™ CART Development Service Targeting Infectious Diseases
• One-Stop Allogeneic Cell Therapy Development Services
  • Allogeneic CAR-T Therapy Development Services
  • Allogeneic TCR-T Therapy Development Services
  • Allogeneic CAR-NK Therapy Development Services
  • Allogeneic CAR/TCR Cell Design and Engineering Services
  • Other Allogeneic Cell Therapy Development Services
• CellRapeutics™ Anti-HIV CAR Cell Therapy Development
  • HIV CAR Design and Construction
  • HIV CAR Cell Design and Engineering
• CellRapeutics™ Antibody-TCR (AbTCR) Technology
• Organoid-induced Differentiation of Conventional T Cells from hPSCs
• Modular CAR-T Cell Generation with AAV-Cpf1
• High-throughput Screening for T Cell Activity Modulator Discovery
• Nanoparticle Tiny Tech for Programming T Cells
• TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology
  • NR4A Knock Out CAR-T Cell Development with CRISPR Technology
• Virus Specific T Cell (VST) Technology
• Antibody-Coupled T Cell Receptor (ACTR) Platform
• CellRapeutics™ TCR/CAR/Antigen-Engineered Regulatory T Cells (Tregs)
  • CellRapeutics™ CAR-Treg Development
• CellRapeutics™ Chimeric Engulfment Receptor (CER) Technology
• Dendritic Vaccine Development
  • Induction of Antitumor Cytotoxic Lymphocytes Using Engineered Human Primary Blood Dendritic Cells
• Bispecific TCR Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
• One-Stop CAR-Monocyte Therapy Development
• Other Services
  • HLA Typing Service
  • KIR Typing Service
  • HLA Testing
  • Tumor-infiltrating Lymphocytes-based Antibody Discovery Service
  • Dog DLA Genotyping Service
  • Guinea Pig GPLA Genotyping Service
  • Mouse H2 Genotyping Service
  • Rabbit RLA Genotyping Service
  • Rat RT1 Genotyping Service
  • Rhesus Macaque MHC Genotyping Service

Allogeneic CAR/TCR Cell Design and Engineering Services

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Creative Biolabs is dedicated to advancing off-the-shelf therapy development by offering comprehensive allogeneic Cell therapy development services. By leveraging state-of-the-art technologies and a team of experienced scientists, we offer a comprehensive one-stop solution for allogeneic CAR/TCR cell design and engineering. Our expertise spans the entire process, from initial design to final engineering, ensuring the highest quality and efficacy of the engineered cells.

Allogeneic CAR/TCR Cell Development Services

We offer the following services tailored to the specific needs of our clients.

• CAR iNK Cell Design and Engineering Service

Induced pluripotent stem cells (iPSCs) have the ability to differentiate into various types of cells including NK cells, providing an unlimited supply of donor cells for therapeutic use. CAR-modified iNK cells represent a powerful new front in immunotherapy. Creative Biolabs has developed proprietary technology for inducing iNK cells from iPSCs. We expand our innovative offerings by providing specialized CAR iNK cell design and engineering services. Our team of experts utilizes advanced gene-editing technologies, including CRISPR/Cas9, to design CAR iNK cells that are specifically tailored to target cancer cells. With our robust experience and cutting-edge laboratory facilities, Creative Biolabs is committed to driving the next-generation CAR-iNK cell innovations, providing clients with a potent tool to fight cancer more effectively.

• CAR-NKT/TCR-NKT Cell Design and Engineering Service

Creative Biolabs offers cutting-edge CAR-NKT and TCR-NKT cell design and engineering services. Natural killer T (NKT) cells are a unique subset of T cells that exhibit both NK cell and T cell properties, allowing them to launch rapid and robust immune responses. By integrating CAR or TCR structure into NKT cells, Creative Biolabs aims to create potent, tumor-targeting cells that are capable of overcoming the immunosuppressive tumor microenvironment. This innovative approach enhances the flexibility and potency of NKT cells, empowering them to offer a multi-faceted attack against various cancers. Leveraging years of industry expertise and state-of-the-art technologies, our experts provide one-stop services from design to the production of modified NKT cells, making them an invaluable tool in the fight against cancer.

• TRuC Cell Design and Engineering Service

Creative Biolabs offers T-cell receptor fusion constructs (TRuC) design and engineering services. TRuC is a novel immunotherapy, that combines the efficacy of traditional TCR therapies with the enhanced targeting capabilities of CAR therapies. By fusing TCR signaling domains with tumor-specific binding domains, TRuC cells can recognize and attack cancer cells more efficiently, eliminating the limitations typically associated with CAR-T or TCR therapies alone. Scientists at Creative Biolabs leverage our extensive knowledge in molecular engineering and cellular biology to generate TRuC cells tailored to the unique needs of clients. This innovative technology ensures increased precision, efficacy, and safety in targeting and destroying cancer cells.